雅培Abbott Laboratories （ABT）2023年年度报告「NYSE」（英文版）（86页）.pdf

1、2023 ANNUAL REPORTTABLE OF CONTENTS1 Letter to Shareholders5 Abbott 20236 From Data to Decisions8 Laboratory Diagnostics10 Rapid Diagnostics 12 Vascular14 Electrophysiology16 From Insight to Innovation18 Structural Heart20 Neuromodulation22 Heart Failure Management24 Cardiac Rhythm Management26 From

2、 Engagement to Empowerment28 Medicines30 Nutrition32 Diabetes Care34 The Future in Fast Forward36 Financial ReportThroughout our long history,we have continually reinvented Abbott to meet the needs of every age and stage of a persons life,innovating to create leading-edge technologies that empower i

3、ndividuals to take ever-increasing control over their own health.We believe the best medical products are those that help the most people.With a focus on maximizing broad access and af ordability across our businesses nutrition,medicines,medical devices,and diagnostics were working to help more peop

4、le in more places meet their most urgent healthcare needs.In a constantly evolving environment that requires visionary leadership,we are well-positioned to continue delivering long-term,sustainable growth and shareholder returns.Front Cover:ZULEYMA SANTOSLOS ANGELES,CALIFORNIA,USAHEARTMATE 3Zuleyma

5、relies on Abbotts HeartMate 3 Left Ventricular Assist Device,a mini heart pump for patients in advanced-stage heart failure.DEAR FELLOW SHAREHOLDER:2023 was the year weve been working toward.With all four of our major businesses again delivering consistently strong performance,Abbott accelerated its

6、 base-business growth and its momentum.In our 135th anniversary year,Abbott again demonstrated the resilience,the creativity,and the commitment needed to meet the challenges of the present and the vast potential of the future of healthcare.ROBERT FORD Chairman of the Board and Chief Executive Office